Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study

Multiple lines of evidence suggest that a deficiency of Fragile X Mental Retardation Protein (FMRP) mediates dysfunction of the metabotropic glutamate receptor subtype 5 (mGluR(5)) in the pathogenesis of fragile X syndrome (FXS), the most commonly known single-gene cause of inherited intellectual disability (ID) and autism spectrum disorder (ASD). Nevertheless, animal and human studies regarding the link between FMRP and mGluR(5) expression provide inconsistent or conflicting findings about the nature of those relationships. Since multiple clinical trials of glutamatergic agents in humans with FXS did not demonstrate the amelioration of the behavioral phenotype observed in animal models of FXS, we sought measure if mGluR(5) expression is increased in men with FXS to form the basis for improved clinical trials. Unexpectedly marked reductions in mGluR(5) expression were observed in cortical and subcortical regions in men with FXS. Reduced mGluR(5) expression throughout the living brains of men with FXS provides a clue to examine FMRP and mGluR(5) expression in FXS. In order to develop the findings of our previous study and to strengthen the objective tools for future clinical trials of glutamatergic agents in FXS, we sought to assess the possible value of measuring both FMRP levels and mGluR(5) expression in men with FXS. We aimed to show the value of measurement of FMRP levels and mGluR(5) expression for the diagnosis and treatment of individuals with FXS and related conditions. We administered 3-[F-18]fluoro-5-(2-pyridinylethynyl)benzonitrile ([F-18]FPEB), a specific mGluR 5 radioligand for quantitative measurements of the density and the distribution of mGluR(5)s, to six men with the full mutation (FM) of FXS and to one man with allele size mosaicism for FXS (FXS-M) Utilizing the seven cortical and subcortical regions affected in neurodegenerative disorders as indicator variables, adjusted linear regression of mGluR(5) expression and FMRP showed that mGluR(5) expression was significantly reduced in the occipital cortex and the thalamus relative to baseline (anterior cingulate cortex) if FMRP levels are held constant (F(7,47) = 6.84, p < 0.001).These findings indicate the usefulness of cerebral mGluR(5) expression measured by PET with [F-18]FPEB and FMRP values in men with FXS and related conditions for assessments in community facilities within a hundred-mile radius of a production center with a cyclotron. These initial results of this pilot study advance our previous study regarding the measurement of mGluR(5) expression by combining both FMRP levels and mGluR(5) expression as tools for meaningful clinical trials of glutamatergic agents for men with FXS. We confirm the feasibility of this protocol as a valuable tool to measure FMRP levels and mGluR(5) expression in clinical trials of individuals with FXS and related conditions and to provide the foundations to apply precision medicine to tailor treatment plans to the specific needs of individuals with FXS and related conditions.